

Review

Beyond β -Adrenergic Receptor Brake: Compartment-Selective GRK2 Programs from Heart Failure to Cardio-Oncology

Cody Reid Dotson, Lilly Underwood and Priscila Y. Sato *

Division of Cardiovascular Disease, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA

* Correspondence: priscilasato@uabmc.edu; Tel.: +1-205-934-0372

Abstract

Sustained neurohormonal stress, adverse myocardial remodeling, and inflammation are major components of heart failure (HF) progression. Alterations in circulating neurohormonal signaling are directly sensed by the β -adrenergic receptor (β AR), a system mainly responsible for chronotropic and inotropic cardiac responses. β ARs are regulated by G-protein-coupled receptor (GPCR) kinase 2 (GRK2). Within this context, decades of study have unraveled mechanistic details on how GRK2 canonically imposes a “brake” on β ARs and other GPCR-mediated signaling. Notably, an expanding body of evidence demonstrates that GRK2 functions in a highly compartment- and cell-dependent manner, with roles extending far beyond GPCR regulation. These noncanonical activities span metabolic control, maintenance of organelle integrity, and regulation of inter-cellular signaling networks, particularly those governing immune–vascular interactions. In this review, we will discuss recent advances in our understanding of the cell-specific functions of GRK2, its emerging biological roles in cardiac diseases, and the opportunities these findings present for advancing mechanistic insights in cardio-oncology. We propose that the therapeutic value of GRK2 is directly dependent on a deeper understanding of its noncanonical functions in a compartment- and cell-specific manner within a disease-specific context.

Keywords: GRK2; heart failure; β -adrenergic receptors; ischemia/reperfusion; cardio-oncology; anthracyclines; immune checkpoint inhibitors

1. Introduction

Heart failure (HF) is a progressive cardiovascular disorder in which impaired cardiac function limits the heart’s ability to maintain sufficient blood flow to peripheral tissues. Paradoxically, chronic sympathetic nervous system (SNS) stimulation is a major driver of this process. While SNS activation supports early increases in cardiac output, chronic adrenergic signaling accelerates remodeling, promotes arrhythmias, and increases mortality [1–3]. On the organ level, this causes the heart to gradually lose its ability to increase contractile strength. At the receptor level, cardiomyocytes undergo downregulation and uncoupling of β ARs, limiting stress-induced increases in contractility, commonly described as loss of inotropic reserve [2,4,5].

GRKs directly regulate β AR desensitization through agonist-dependent receptor phosphorylation, which promotes β -arrestin recruitment and uncoupling from G-protein signaling [6,7]. There are seven GRK isoforms, whereas the major isoforms in the heart are GRK2 and GRK5. For a detailed biochemical introduction of the GRK family and role of GRKs in GPCR-signaling, refer to this comprehensive review [7]. Early studies in human HF



Academic Editor: Mauro Salvi

Received: 20 June 2026

Revised: 24 July 2026

Accepted: 28 July 2026

Published: 31 July 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and

conditions of the [Creative Commons](#)

[Attribution \(CC BY\)](#) license.

showed that GRK2 expression and activity were increased in failing ventricles and that this increase coincided with impaired β AR responsiveness [3,5]. Later work showed that GRK2 levels were elevated in peripheral blood cells, mirroring those in the myocardium and correlating with HF severity [5,8]. These findings placed GRK2 as the nexus of sustained sympathetic drive and diminished adrenergic reserve in HF.

Importantly, recent studies have shown that GRK2 has a broader cellular impact that goes beyond the canonical “ β AR brake.” These noncanonical functions of GRK2, including its role in metabolic remodeling, mitochondrial injury, immune–vascular signaling, and treatment-related cardiotoxicity, are discussed in later sections of this review. Table 1 summarizes localization, cell-type expression, and major contexts related to GRK2 addressed in this review.

Table 1. GRK2 role in context- and cellular-type-dependent compartmentalization (OSS = Oscillatory-Shear Stress; DOX = doxorubicin; ICI = immune checkpoint inhibitor).

Context	GRK2 Level/State	Compartment(s)	Immune Effects	Metabolic Effects	Biomarker Potential	Therapeutic Targets	Key Refs
Acute I/R	GRK2 degradation; Pin1/AKT loss	Membrane ↓; Mitochondrial trafficking risk	Neutrophil influx shaped by fibroblast GRK2	AKT pathway suppression	—	Preserve GRK2/AKT; inhibit cal-pain/proteasome (timed)	[9,10]
Post-Acute I/R	ERK → Ser670; Hsp90 → mito GRK2	Mitochondria ↑	Pro-death signaling; mPTP opening	ROS ↑; Apoptosis ↑	—	Block Ser670; disrupt Hsp90 docking; mPTP modulators	[11,12]
Chronic HF	GRK2 ↑ (myocardium, lymphocyte)	Membrane & Mitochondria	β -AR dysfunction; lymphocyte GRK2 tracks severity; exercise reduced	FA catabolism altered; β -AR-mitochondrial response impaired	PBMC GRK2 predicts survival	β ARKct, paroxetine; gene therapy; exercise	[8,13,14]
Endothelium (OSS)	GRK2 S29 phosphorylation	Nucleus/AP-1 axis	ICAM1/VCAM1 ↑ → leukocyte adhesion	AMPK ↓ via NR4A1/LKB1	—	Target GRK2/AP-1; shear normalization	[15,16]
Macrophage Polarization	GRK2 translocation; EP4 desensitization	Membrane ↔ Cytosol	M2 suppressed when GRK2 ↑; paroxetine restores	PKM2 (S406/K433) → glycolysis ↓	—	GRK2 inhibitors; EP4 agonism; metabolic co-therapy	[17,18]
Lymphocyte/Neutrophil Migration	GRK2 with GRK3/5/6 networks	Membrane	Chemotaxis tuning; cell-type specific	—	PBMC GRK2 (HF)	Combinatorial GRK targeting	[19,20]
Anthracycline (DOX)	Early GRK2 ↓ (heart, PBMC)	Membrane/Cyto	Endothelial & immune changes precede damage	Mitochondrial stress; Ca ²⁺ dysregulation	Early sentinel	Serial PBMC GRK2; cardio-onc surveillance	[21,22]
Immunotherapy (ICI)	Unknown baseline GRK2 signature	Immune Cells	Myocarditis/peri via T-cell hyperactivation	—	GRK2 as risk stratify	Prospective biomarker + chemotaxis assays	[23]

2. GRK2—The “Brake” on β AR Signaling in Heart Failure

2.1. GRK2 Upregulation and Impaired β AR Responsiveness

GRK2 is a negative regulator of β AR and a major contributor to receptor desensitization in HF [7]. Multiple studies have shown that in human HF, β 1AR is diminished, with a concomitant decrease in responsiveness to β -agonism, a phenomenon linked to upregulation of GRK2 expression and activity [1–3]. Using failing human myocardial tissue,

an inverse correlation was observed between GRK activity and β AR-mediated cAMP generation [5]. This was further supported by studies in mice overexpressing GRK2, in which β AR responsiveness was decreased [14]. Thus, GRK2 was positioned as a contributor to β AR desensitization and the progressive loss of inotropic reserve in HF.

GRK2 is ubiquitously expressed, and its role as a receptor “brake” is essential to cardiac biology. In human HF, GRK2 expression and activity in circulating lymphocytes mirror those in the myocardium and are associated with reduced β AR responsiveness and HF severity [5,6,8,13]. Thus, sympathetic overdrive influences GRK2 upregulation also in non-cardiac cells, including lymphocytes, which have been postulated as a biomarker for HF progression [5,6,24–26].

2.2. Chronic SNS Signaling, GRK2 Activation, and a Self-Perpetuating Cycle

Chronic SNS activation is a hallmark of HF and contributes to adverse outcomes [4,24]. Sustained catecholamine exposure contributes to β AR downregulation and desensitization, with GRK2 activity contributing to this detrimental feedback loop. This increase in GRK2 activity leads to diminished β AR sensitivity and coupling, thereby decreasing responsiveness to β AR stimulation and subsequently compromising contractility. Decreased adrenergic response augments SNS activation, leading to further increases in circulating catecholamines and perpetuating signaling that promotes HF progression [6,27].

Thus, myocardial GRK2 levels correlate with clinical severity and cardiac functional readouts and are higher under conditions of augmented adrenergic stimulation, whereas decreased β AR signaling is associated with reduced GRK2 expression [4,7,8]. Collectively, these findings support the concept that sustained sympathetic stimulation contributes to GRK2 upregulation and progressive impairment of β AR signaling in HF.

2.3. Reversal Logic: GRK2 Inhibition Restores β AR Signaling and Contractility

A major strength of the GRK2 “brake” model is its reversibility, that is, inhibiting GRK2 can partially restore cellular function. In failing cardiomyocytes, expression of β AR carboxy-terminus (β ARKct) peptides, which act as competitive inhibitors to GRKs by binding G $\beta\gamma$ subunits, improves basal and β -agonist-stimulated cAMP production, restoring contractile responsiveness [14,28]. This “reversal logic” is supported by multiple in vivo genetic and preclinical translational approaches [7,29–32]. Cardiac expression of β ARKct peptides enhances contractility and protects against adrenergic dysfunction in transgenic models and via viral-mediated gene delivery, establishing early proof of concept for GRK2 inhibition [33,34]. Complementary gene-targeted studies showed that β ARKct expression can prevent or delay the development of cardiac dysfunction in a genetic HF model, further supporting the potential of GRK2 inhibition as a therapeutic strategy [14,29].

In separate studies, by using a transgenic mouse model containing GRKInh, a peptide inhibitor of GRK2, Quatterer and colleagues showed that GRKInh mice exhibit cardioprotective effects post-myocardial infarction (MI) with reduced cardiomyocyte death and attenuated maladaptive metabolic remodeling [30,35]. The serotonin-reuptake inhibitor (SSRI) paroxetine has been shown to inhibit GRK2 [36,37]. Use of paroxetine in mice post-MI improves adrenergic contractile reserve and ventricular function [32,36]. Moreover, an inhibitor derived from the paroxetine scaffold with higher selectivity for GRK2 produced enhanced dobutamine inotropic responses [31]. These studies establish GRK2 as a central mediator of β AR dysfunction in HF and identify it as a therapeutic target to improve cardiac function [3,28,30,32–37].

3. GRK2 in Chronic HF: New Metabolic and Neurohormonal Roles

3.1. GRK2 as a Therapeutic Target in HF

HF treatment strategies have improved patient quality of life and mortality rates. Yet, these strategies delay disease progression without providing a cure. In fact, heart disease remains the number one cause of death in the US and the world. A large body of evidence demonstrates that GRK2 is consistently upregulated and activated across multiple HF models, and that its activity can be selectively modulated through interference of protein–protein interactions or inhibition of its catalytic function [7,38]. As a result, several therapeutic strategies targeting GRK2 have been developed, including peptide-based inhibitors (i.e., β ARKct, GRK2Inh), small-molecule approaches with GRK2-inhibitory activity (e.g., paroxetine), and strategies designed to prevent GRK2 recruitment (e.g., disruption of the $G\beta\gamma$ –GRK2 interface) [28,32,37,39].

While small-animal studies are important models that enable focused testing, pre-clinical experimentation is imperative for informing clinical trials. In a post-MI porcine model, AAV6 β ARKct gene therapy supported GRK2 inhibitory strategies, improving left ventricular hemodynamics, and normalizing neurohormonal markers [33]. Similar results were obtained in a mini-swine HF model using a novel GRK2 inhibitor [31]. These findings position myocardial GRK2 inhibition as a viable long-term therapeutic strategy rather than merely a transient experimental intervention.

3.2. GRK2 and Cardiac Metabolism: Insulin Signaling and Glucose Utilization

HF is characterized by impaired myocardial energetics that lead to contractile dysfunction [40]. GRK2 participates in linking neurohormonal stress and metabolic remodeling by inhibiting glucose uptake and promoting insulin resistance in the injured heart [7,11,41,42]. This occurs in part through GRK2-mediated phosphorylation of IRS1, thereby limiting GLUT4 translocation and reducing glucose utilization [41]. GRK2 can also translocate to mitochondria, where it regulates glucose oxidation [12]. Thus, GRK2 integrates adrenergic signaling and metabolic regulation, highlighting its multifaceted role in HF progression.

GRK2-dependent cardiac metabolic dysfunction can also be therapeutically targeted. Pharmacologic and peptide-based GRK2 inhibition improves metabolic features and cardiac function in HF models, including improved markers of mitochondrial organization and contractile responsiveness [43]. These studies provide a broader view of GRK2 as a remodeling kinase involved in physiological and pathological processes with a footprint that extends beyond β AR uncoupling to encompass the metabolic machinery that sustains myocardial performance during chronic disease [12,41–43].

More recently, studies on partial GRK2-biased β_2 AR agonists identified compound 15 to selectively enhance skeletal muscle glucose uptake via mTOR while minimizing Gs/cAMP signaling and β -arrestin recruitment [44]. This compound improved glucose homeostasis as measured by glucose tolerance tests. It also improved fat and lean mass with minimal cardiac atrial contractility impact when combined with GLP-1 therapy [44]. Notably, long-term in vivo global metabolic impact of compound 15 remains to be fully characterized. This is particularly relevant as β -cell-specific GRK2 knockout increases insulin sensitivity as measured by hyperinsulinemic-euglycemic clamps [42], global-GRK2 heterozygous mice have decreased weight gain in an obesogenic regimen and increased insulin sensitivity [45], and GRK2 inhibition has been proposed to potentiate GLP1-receptor agonism [46]. Overall, the studies support an important role for GRK2 in metabolic regulation.

3.3. Adrenal GRK2 and Systemic Sympathetic Overactivity

Adrenal regulation is a major determinant of circulating catecholamine levels, and dysregulation of this organ amplifies systemic adrenergic stress. Mechanistic studies

show that upregulation of adrenal GRK2 desensitizes α 2AR in chromaffin cells, thereby increasing catecholamine release and worsening sympathetic overdrive [24].

Adrenal-targeted GRK2 inhibition or gene deletion reduces circulating catecholamines, improving post-MI cardiac β AR signaling and function [25,47]. Moreover, exercise training, an established HF treatment, has also been linked to restoration of the adrenal GRK2/ α 2AR axis, offering an additional benefit in reduced sympathetic overdrive in trained HF models [26]. Together, these findings support a multi-compartment view of GRK2 biology in HF, in which myocardial and adrenal GRK2 influence both local signaling and systemic neurohormonal activation.

4. Ischemia/Reperfusion (I/R): Compartment-Specific GRK2 Signaling, Cell Death, and Metabolic Outcomes

4.1. Acute I/R: Signs of GRK2 Degradation and Collapse of Pro-Survival Signaling

I/R injury involves many signaling pathways that are major determinants of cellular outcomes including activation of kinase cascades and proteostasis programs. The acute phase of I/R injury spans from minutes up to 1 h and is reported to involve phosphorylation-dependent GRK2 degradation, coupled with concurrent loss of pro-survival Akt signaling and Pin1 [9]. This pattern highlights that even during the acute stages of reperfusion, there are subtle but important changes in signaling homeostasis that impact cell fate, reinforcing that “timing” is central for intervention during the reperfusion phase of I/R injury. Figure 1 illustrates acute phase changes pertinent to I/R.




Figure 1. Timeline representation of acute and post-acute I/R myocardial events linked to GRK2. Created in BioRender. Dotson, R. (2026) <https://BioRender.com/0rziyfg>.

4.2. Post-Acute I/R: ERK-Dependent Ser670 Phosphorylation, Hsp90 Binding, and Mitochondrial Targeting

During the post-acute stages of I/R (post-60 min), ERK-dependent phosphorylation of GRK2 at Serine 670 promotes Hsp90 binding and mitochondrial translocation, thereby promoting cardiomyocyte death [11,48]. Notably, the association of Hsp90 with GRK2 is a key determinant for the proper maturation and stability of the kinase [48]. Thus, localization, abundance, and phosphorylation status of GRK2 are dynamically altered during the reperfusion phase and contribute to I/R injury. Figure 1 illustrates post-acute changes pertinent to this reperfusion phase.

4.3. Limiting Mitochondrial GRK2 Preserves Glucose Oxidation and Reduces Injury

Genetic models provide compelling evidence that mitochondrial translocation of GRK2 contributes to post-I/R dysfunction. Mice harboring the GRK2 Ser670Ala (S670A) mutation, which hinders phosphorylation-dependent mitochondrial targeting of GRK2, exhibit reduced cardiomyocyte death and improved cardiac functional recovery post 24h of IR [12]. This effect is partly attributable to the prevention of GRK2 mitochondrial translocation, which preserves glucose oxidation and maintains pyruvate dehydrogenase activity [12]. Importantly, because this mutation is expressed ubiquitously, potential effects in non-

cardiac tissues and their indirect contributions to the observed cardiac phenotype must also be considered. Nonetheless, data support that mitochondrial GRK2 is an important contributor to post-ischemic metabolic dysfunction.

4.4. Multi-Cellular Regulation of I/R: Cardiomyocyte vs Fibroblast GRK2

I/R outcomes depend on coordinated responses across multiple cardiac cell types. GRK2 directly influences cardiomyocyte cell survival, as cardiomyocyte-specific genetic ablation of GRK2 reduces apoptosis, limits infarct size, and improves functional recovery following I/R [49,50]. Additionally, GRK2 in cardiomyocytes is involved in mitochondrial cell death pathways [9,11]. GRK2 in cardiac fibroblasts regulates acute immune-cell recruitment and promotes subsequent remodeling responses. Fibroblast-specific GRK2 knockout reduces infarct size, preserves cardiac function, decreases fibrosis, and is associated with reduced neutrophil infiltration and TNF- α signaling [10]. These observations suggest that GRK2 functions across multiple cardiac cell types to regulate injury-induced immune responses and repair mechanisms, shaping both the severity of the initial insult and the long-term remodeling outcome [10,49].

4.5. NO/S-Nitrosylation Cross-Talk Converges on GRK2

Nitric oxide (NO) is a critical mediator of cardioprotection during I/R injury. While during reperfusion excessive ROS generation contributes to cellular damage, physiological NO signaling can limit injury by improving coronary perfusion, reducing mitochondrial dysfunction, and attenuating inflammatory responses [51,52]. One important mechanism underlying these NO protective effects is protein S-nitrosylation, a reversible post-translational modification in which NO covalently modifies cysteine residues, thereby altering protein activity, localization, and protein–protein interactions [53]. GRK2 is regulated by redox-dependent modifications. In particular, S-nitrosylation of GRK2 at cysteine 340 (C340) inhibits its kinase activity, preventing excessive receptor desensitization and maladaptive signaling during cardiac stress [54,55]. During I/R injury, NO-mediated nitrosylation of GRK2 C340 has been proposed as an endogenous cardioprotective mechanism that limits GRK2 activation, preserves β -adrenergic signaling, and reduces myocardial injury [54,55]. Loss of this regulatory modification exacerbates cardiac dysfunction, highlighting the importance of GRK2 C340 nitrosylation as a key node linking NO signaling to cardioprotection [54,55]. Notably, this NO-modification in GRK2 is also linked to age-related cardiac dysfunction [56].

5. Immunovascular GRK2 Programs: Endothelium, Leukocyte Trafficking, and Macrophage Immunometabolism

5.1. Endothelial GRK2: Adhesion Programs and Inflammatory Recruitment

Cardiac injury and remodeling are modulated by cardiomyocyte stress responses and by immune-cell recruitment. The vascular endothelium is a key gatekeeper in this process, regulating mechanical forces and inflammatory cues that control leukocyte adhesion and migration. Recent mechanistic work shows that disrupted blood flow promotes GRK2 Serine 29 phosphorylation with downstream AP1 activation, increasing ICAM 1/VCAM 1 expression while decreasing AMPK signaling, linking endothelial GRK2 to both inflammatory adhesion programs and metabolic tone [15,16]. Serine 29 of GRK2 is located within the calmodulin binding domain, and phosphorylation by PKC has been shown to abolish GRK2 inhibition by calmodulin [57]. Causal support for an endothelial role of GRK2 also comes from knockout mice with endothelium-selective knockout of GRK2 [58]. Endothelial GRK2 deficiency impaired vascular homeostasis, enhanced mitochondrial ROS production and inflammatory signaling, and led to structural and functional vascular dysfunction [58].

5.2. GRK2 and the Akt/eNOS Axis

In parallel with adhesion signaling, endothelial homeostasis is critically governed by NO production. Mechanistic evidence links GRK2 to endothelial NO signaling by interactions with Akt, affecting eNOS activation and NO bioavailability [54,59]. This provides a molecular basis for shared NO-GRK2 signaling axis across vascular and myocardial compartments [54,59].

5.3. Leukocyte Migration: GRK Networks and Chemokine GPCR Regulation

The healthy myocardium contains resident macrophage populations that persist following injury and shape the early inflammatory environment [60]. After MI, neutrophils are among the first blood-derived leukocytes to enter the myocardium. Resident cardiac macrophages help drive this early extravasation through TLR9/MyD88/CXCL5 signaling [61]. Monocyte recruitment occurs in two phases, with Ly6C^{hi} monocytes dominating the early inflammatory phase and Ly6C^{lo} monocytes accumulating later to support angiogenesis and collagen-based repair [62]. Studies in rheumatoid arthritis, Weibel-Palade body formation, and multiple sclerosis have suggested that GRK2 protein levels in leukocytes may control the intensity and duration of certain chemokine-triggered signaling [17,63–65]. An illustration of timing and immune contribution post-MI is shown in Figure 2.




Figure 2. Schematic illustration of early and late immune events in response to MI. Created in BioRender. Dotson, R. (2026) <https://BioRender.com/fws6w8l>.

Once leukocytes enter the tissue, their migration and positioning depend on chemokine GPCR signaling and receptor desensitization, both of which are regulated by GRKs. Combinatorial GRK depletion studies showed that leukocyte migration depended on specific GRK isoform involvement, emphasizing that GRK2 operates within an extensive GRK network that tunes immune-cell trafficking in a context- and cell-type-dependent manner [19]. Nonetheless, the specific role of GRK2 in leukocytes in the context of MI remains less understood and warrants further investigation.

5.4. GRK2 Framework in the Context of Macrophage Immunometabolism

After the initial neutrophil wave, circulating monocytes are recruited to the injured myocardium via chemokine signaling. Upon entering the tissue, monocytes differentiate into a spectrum of macrophage states with distinct functional properties [66]. In murine MI, Ly6C^{hi} monocytes dominate the early inflammatory phase (roughly days 1–4), clearing necrotic debris and modulating proteolytic and inflammatory signaling (Figure 2). As inflam-

mation resolves, Ly6C^{lo} monocytes and macrophages become more prominent and support efferocytosis, angiogenesis, myofibroblast expansion, and collagen deposition [62,67].

Macrophage behavior depends on both lineage and the local metabolic milieu. Their activation states are tightly linked to metabolic reprogramming; a process that may be linked to GRK2 biology. Glycolysis, oxidative phosphorylation, and related metabolic pathways help distinguish inflammatory from reparative macrophage programs [68,69]. GRK2 has been linked to pathways that influence macrophage polarization and glycolysis, including EP4-cAMP-pCREB signaling and PKM2-related metabolic regulation [17,18]. These findings raise the possibility that GRK2 may influence macrophage behavior during tissue injury.

5.5. Adaptive Immune Recruitment: Delayed Lymphocyte Accumulation and Potential GRK2 Control Points

Adaptive immune-cell recruitment follows the early innate immune response and becomes increasingly evident during the first week post-MI (Figure 2). Flow cytometric analyses in murine MI models show that CD8⁺ T-cells, $\gamma\delta$ T-cells, B cells, and myeloid dendritic cells peak around day 7 post-MI [70]. In the same setting, Th1 cells and regulatory T-cells (Tregs) are the predominant CD4⁺ T-cell subsets in the infarcted myocardium [70]. Timely reperfusion attenuates this later adaptive immune wave, supporting the idea that lymphocyte recruitment is temporally downstream of the initial innate response.

Recent transcriptomic analyses refine this view by showing that the healthy heart already contains resident or tissue-associated B- and T-cell populations and that, following MI, these cells sustain inflammatory and remodeling-associated programs [71]. Post-MI, cardiac T-cells upregulate transcripts associated with cytokine production and cytotoxicity, including *Ccl5*, *Ifng*, *Tnf*, *Gzmk*, and *Prf1*, whereas B cells upregulate activation-associated and matrix-related programs, including *Il6*, *Il1rn*, *Ccl6*, and collagen transcripts [71]. Notably, these altered transcriptional states can last beyond the initial lymphocyte wave (Figure 2; days 5–7), supporting a role for the adaptive arm in the transition from early injury to chronic remodeling.

Although the role of GRK2 in cardiac lymphocytes following ischemic injury remains poorly defined, existing evidence points to several mechanisms through which GRK2 may influence adaptive immune responses in the injured myocardium. In primary immune cells, combinatorial GRK depletion studies show that GRK2, together with other GRKs such as GRK6, regulates chemokine receptor signaling in a cell-type- and receptor-dependent manner, altering both T-cell and B-cell chemotaxis and tissue localization in vivo [19]. T- and B-cell infiltration into the myocardium depends on coordinated chemokine gradients and their cognate receptors, suggesting that GRK2-mediated receptor desensitization likely influences immune-cell recruitment and timing post-MI.

Beyond migration, GRK2 can also directly regulate T-cell effector signaling. In human T-cells, GRK2 is required for T-cell receptor (TCR)-induced transactivation of CXCR4, formation of a TCR-CXCR4 signaling complex, recruitment of PI3K γ /PREX1, and robust cytokine secretion [19,72]. Conversely, GRK2 depletion or pharmacologic inhibition attenuates these responses [19,72]. Moreover, GRK2-mediated desensitization of the Sphingosine-1-Phosphate Receptor 1 (S1PR1) is critical to both T-cell maturation and blood chemotaxis [73]. Together, these data support a working model in which GRK2 may influence not only the timing and extent of adaptive immune-cell entry into the injured heart but also the functional output of infiltrating T-cells once they populate the tissue. GRK2 in adaptive immune cells may integrate chemokine responsiveness, antigen receptor cross-talk, and cytokine output to shape the evolution from acute inflammation to persistent immunopathology.

6. Anthracycline Cardiotoxicity: Trial Evidence, Risk Stratification, and Mechanism-Linked Biomarker Opportunities

6.1. Clinical Framework and Definitions

Anthracyclines remain a cornerstone of cancer therapy, but their clinical use is constrained by cumulative myocardial injury that can progress from subclinical biomarker and imaging abnormalities to overt HF. In contemporary cardio-oncology management, this spectrum is commonly captured under the term cancer therapy-related cardiac dysfunction (CTRCD). Current guidance from the European Society of Cardiology (ESC) and the International Cardio-Oncology Society (IC-OS) has helped standardize definitions, severity grading, and surveillance pathways across studies and clinical practice [74,75].

The 2022 ESC cardio-oncology guidelines and the IC-OS consensus statement provide the current clinical system for assessing anthracycline-associated cardiovascular injury [74,75]. These documents harmonize definitions of CTRCD, myocarditis, vascular toxicity, arrhythmias, and related complications, and recommend risk-adapted monitoring using cardiac biomarkers, echocardiography, global longitudinal strain (GLS), and selected use of cardiac magnetic resonance imaging. It is because of this precise monitoring structure that cardio-oncology cohorts provide the ideal platform to meaningfully assess GRK2's diagnostic and prognostic value.

6.2. Troponin-Guided Strategies: Classic Evidence and Modern Boundary Conditions

Cardiac troponins are highly sensitive biomarkers of myocardial injury, reflecting the release of intra-cellular contractile proteins from cardiomyocytes into the circulation in response to cellular damage or stress [76]. The development of biomarker-guided cardioprotection in cardio-oncology was driven by studies showing that troponin elevation identifies early myocardial injury. Cardinale and colleagues showed that patients with troponin I elevation after high-dose chemotherapy had a smaller decline in left ventricular ejection fraction (LVEF) when the ACE-inhibitor enalapril was started early [77]. Although the study established the feasibility of injury-guided cardiac intervention, its findings cannot be readily generalized to routine prophylactic use in standard anthracycline-treated populations. The enrolled patients were identified by post-treatment troponin elevation after high-dose chemotherapy, a population distinct from those receiving conventional adjuvant anthracycline therapy.

Subsequent trials refined the limits of that approach in lower-risk and more contemporary anthracycline-treated populations. In Cardinale's "ICOS-ONE" study, starting enalapril in all patients before chemotherapy was not superior to a troponin-triggered strategy in which enalapril was introduced after biomarker elevation was observed. This suggests that universal prophylaxis may not add value in relatively low-risk patients receiving modest cumulative anthracycline doses [78]. Likewise, in the "Cardiac CARE" study by Henriksen and colleagues, high-sensitivity cardiac troponin I was used to identify patients at higher risk during anthracycline therapy, but subsequent cardioprotection with carvedilol plus candesartan did not prevent short-term decline in LVEF [79]. Together, these studies suggest that troponin remains highly valuable for risk enrichment and injury detection. However, translating troponin positivity into effective, uniform preventive pharmacotherapy has been more difficult than early proof-of-concept studies implied.

6.3. Neurohormonal Prophylaxis: Modest, Endpoint-Dependent Benefit

Despite being the more conventional approach, prophylactic neurohormonal blockade has yielded mixed results that vary according to the endpoint evaluated. In the Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) trial, concomitant candesartan attenuated the early decline in LVEF during adjuvant anthracycline-

containing therapy for early breast cancer, whereas metoprolol alone did not improve the primary imaging endpoint. Extended follow-up suggested some favorable effects of candesartan on ventricular remodeling and strain, but at 2 years, it had not prevented the decline in LVEF [80].

A similar pattern was observed in the Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity (CECCY) trial, which tested carvedilol in women with HER2-negative breast cancer receiving anthracycline-based chemotherapy. Carvedilol did not reduce the primary endpoint of early LVEF decline, but it was associated with lower troponin release and less diastolic dysfunction [81]. Taken together, PRADA and CECCY suggest that neurohormonal prophylaxis may confer modest biological or subclinical benefit, but the magnitude and clinical relevance of that benefit depend heavily on the endpoint assessment, the baseline cardiovascular risk of the population, and the anthracycline regimen itself. This is likely why current practice favors selective use in higher-risk patients rather than a blanket prophylaxis for all.

6.4. Dexrazoxane: Most Consistently Supported Pharmacologic Prevention

Compared with other pharmacologic strategies, dexrazoxane has the most consistent evidence supporting its ability to prevent anthracycline cardiotoxicity [82,83]. The mode of action for dexrazoxane is not entirely understood, but it is postulated that at least in part, it acts as an iron-chelator, involved in reducing ROS. Randomized trials in advanced or metastatic breast cancer showed that dexrazoxane reduced cardiac events and symptomatic HF. In those studies, there was no clear evidence that it reduced antitumor efficacy or tumor response [83]. Recent systematic studies further support reduced HF and cardiotoxicity in adults receiving anthracycline-based therapy, with no clear evidence of diminished oncologic benefit [84,85].

The need for cardioprotective strategies is greatest when anthracycline therapy cannot be interrupted due to oncologic necessity. This is especially true for patients with high cumulative drug exposure or previous anthracycline treatment, which elevates the risk of cardiac dysfunction. Dexrazoxane stands apart from beta-blockers and renin–angiotensin system (RAS) inhibitors because it has the strongest direct evidence for reducing cardiac injury while allowing anthracycline treatment to continue. To date, there are no studies on dexrazoxane's impact on GRK2 or vice versa. However, dexrazoxane's proposed mechanism of action involves preventing the formation of oxygen-free radicals [86] and mitochondrial GRK2 upregulation promotes superoxide and ROS [11,38]. Although we speculate a potential mechanistic convergence, the role of cardiac GRK2 in this context remains unknown but warrants further investigation.

6.5. Translational Niche: GRK2 as a Candidate Biomarker Axis in Cardio-Oncology

Anthracycline surveillance is valuable not only for guiding early preventive care but also for serving as a clinically well-defined platform for the validation of translational biomarkers. Patients are longitudinally monitored with troponins, natriuretic peptides, echocardiography, GLS, and, in some cases, cardiac magnetic resonance imaging [79,80,87]. The longitudinal surveillance schedule provides an opportunity for repeated sampling time points at which GRK2 expression can be evaluated [88]. By capturing compartment-specific stress responses, myocardial or immune-cell GRK2 may provide information not reflected by current surveillance biomarkers. Cardio-oncology cohorts offer a unique opportunity to test whether GRK2 improves the detection and risk stratification of cardiotoxicity, especially when traditional biomarkers are inconclusive.

7. Immune Checkpoint Inhibitor (ICI) Myocarditis: Spectrum, Diagnostics, Mechanisms, and Treatment Escalation

7.1. Clinical Phenotype and Registry Outcomes

ICIs are revolutionary immunotherapy drugs that are used to treat patients with a variety of cancers. Among the toxicities identified with ICI therapy, myocarditis has emerged as a clinically significant adverse event. Early reports indicate that this primarily arises from patients receiving combinatory immune checkpoint blockade [89]. Multicenter registry data showed myocarditis often occurs early after initiation of therapy, can present without reduction in EF, and carries high rates of major adverse cardiac events (MACE), supporting the need for early recognition and management [90]. Evidence from large clinical trial datasets estimates ~1% of patients had ICI-induced cardiovascular adverse events where myocarditis mortality was 38%, highlighting the necessity for standardized diagnostic and treatment methods [87].

7.2. Risk Factors and Thymic Predisposition

Among clinical risk factors, concurrent PD-1 and CTLA-4 blockade has been repeatedly associated with a heightened incidence of myocarditis [90]. High-impact evidence points to thymic alterations as susceptibility factors, with thymic epithelial tumors associated with increased incidence/severity and earlier onset of overlapping “myotoxicity” syndromes [91].

7.3. Diagnostic Work-Up: Troponin, Imaging, and Endomyocardial Biopsy (EMB) Grading

Clinical presentation is highly variable, posing challenges for accurate and timely diagnosis. Although current diagnostic approaches rely on a combination of biomarkers and multimodal imaging, EMB remains the definitive diagnostic standard, especially in ambiguous cases. Histological evaluation of EMB specimens from a large ICI-treated cohort demonstrated a continuum of myocardial inflammation, indicating that some patients with low-grade disease may tolerate ongoing ICI therapy without immunosuppressive treatment and underscoring the value of risk-stratified management [92]. Baseline troponin measurement before the initiation of ICI therapy, together with serial monitoring during treatment, is emerging as a practical strategy for the early detection of cardiovascular toxicity. Despite its potential utility, this strategy is not currently considered standard of care and requires additional validation before it can be integrated into routine clinical standard of care for myocarditis detection [93].

7.4. Mechanisms: Immune Tolerance, Macrophage Programs, and the IFN γ Axis

Direct evidence linking GRK2 to ICI myocarditis remains limited, yet current pathogenic models center on immune regulatory pathways in which GRK2 has been shown to play a role. This includes chemokine-dependent immune-cell trafficking, macrophage inflammatory programming, and amplification of cytokine receptor signaling [18,19,72,73]. Mechanistic studies show that checkpoint pathways are vital for immune tolerance in cardiac tissue and that loss of inhibitory signaling can unleash autoreactive responses [94]. Translational murine and human tissue studies support expansion of inflammatory macrophage subpopulations (CXCL9/10-high) induced by IFN γ signaling and highlight the interaction with CD8⁺ T-cells as critical to myocarditis pathogenesis. This identifies the IFN γ axis as a potential target in severe cases [95].

Recent work has identified a CXCL9/10⁺ CCR2⁺ macrophage–CXCR3^{hi} CD8⁺ T-cell axis in ICI myocarditis, supporting the concept that inflammatory cardiac macrophages help sustain cytotoxic T-cell recruitment and retention within the myocardium [96]. In pre-clinical models, both depletion of these macrophages and pharmacologic CXCR3 blockade

reduced myocardial T-cell infiltration and improved survival. Human cardiac biopsy samples showed similar enrichment of CXCR3⁺ T-cells and CXCL9/CXCL10⁺ macrophages [96]. These studies support a contributing role in disease amplification and represent a potential therapeutic target. Collectively, these mechanistic observations suggest that ICI myocarditis arises within an immune signaling landscape that overlaps considerably with established GRK2 function. Notably, separate studies have shown that GRK2 regulate CXCR3 recruitment and modulation post-stimulation [97]. Given the central roles of inflammatory macrophages and cytotoxic T-cells in disease pathogenesis, GRK2 may be an important regulator of immune-cell trafficking and activation within the inflamed myocardium.

7.5. Treatment: Steroids First Line; Escalation and Emerging Trials

First-line therapy for ICI-induced myocarditis remains high-dose corticosteroids; refractory cases may require additional immunosuppression. Case-level evidence supports abatacept (CTLA 4 agonism) for severe steroid-refractory myocarditis, and clinical updates emphasize ongoing trials evaluating abatacept and other steroid-sparing approaches [98,99]. Notably, multicenter registry analyses suggest that both earlier initiation and higher initial steroid dosing improved outcomes with reduction in major adverse events [100].

8. Therapeutic Windows and Translational Design Principles: Compartment- and Cell-Selective GRK2 Targeting

8.1. Timing Matters: Acute vs Post-Acute Injury Signaling

I/R studies show that GRK2 cardiac signaling is not monolithic: initial acute injury features proteostasis-linked GRK2 degradation and loss of survival signaling, while post-acute injury involves serine 670 phosphorylation and mitochondrial trafficking that drives cell death and metabolic impairment (Figure 3) [9,11,12]. This evidence suggests exploring phase-specific interventions to preserve protective signaling, block mitochondrial GRK2 localization, limit injury, and preserve cardiac function.




Figure 3. Schematic illustration for therapeutic windows where GRK2 pharmacological intervention may be advantageous in disease progression. Created in BioRender. Dotson, R. (2026) <https://BioRender.com/7vf38uz>.

8.2. Compartment Logic: “Block Recruitment,” “Block Catalysis,” or “Block Trafficking”

GRK2 can be targeted at multiple mechanistic levels: preventing recruitment to activated GPCRs (β ARKct; $G\beta\gamma$ interface inhibitors), inhibiting catalytic activity (small molecules such as paroxetine), or selectively blocking mitochondrial trafficking

(Ser670/Hsp90 axis; Figure 3) [11,39,101]. Each approach likely produces distinct physiologic and safety characteristics, and the most appropriate strategy may differ in chronic HF, acute I/R, and cardio-oncology cardiotoxicities.

8.3. Cell Specificity: Fibroblast and Endothelial Targeting as Remodeling Modifiers

Fibroblast GRK2 deletion reduces inflammatory infiltration and fibrosis post-I/R, while endothelial GRK2 regulates adhesion programs that govern leukocyte entry [10,16]. This supports cell-type-directed delivery or cell-selective regulatory nodes for therapeutic development—particularly for inflammation-dominant remodeling phenotypes (Figure 3).

8.4. Biomarker Integration: Peripheral Blood Mononuclear Cells (PBMCs) GRK2 Within Guideline Surveillance Frameworks

Human HF data demonstrate that PBMC and lymphocyte GRK2 levels mirror myocardial levels and track severity, and that exercise-associated changes in lymphocyte GRK2 may have prognostic relevance [5,13,88,102]. Translating this concept to cardio-oncology would require rigorous prospective validation alongside established clinical monitoring (troponin/BNP, echo/GLS, CMR in selected cases) as emphasized by current guidelines and consensus definitions [74,75] (Figure 3).

9. Conclusions and Future Directions

GRK2 is uniquely positioned at the intersection of adrenergic receptor regulation, myocardial metabolism, mitochondrial death signaling, and immunovascular biology. Human HF studies established GRK2 elevation as a correlate of adrenergic dysfunction and severity, while genetic and translational interventions demonstrate causality and therapeutic promise [3,5,29,31,33]. I/R injury studies reveal compartment-specific mechanisms (proteostasis-linked early effects; Serine670/Hsp90 mitochondrial trafficking later) that highlight actionable levers [9,11,12]. Multi-cellular studies in fibroblasts and endothelium point to system-level effects on immune recruitment and remodeling [10,16].

In cardio-oncology, anthracycline and ICI cardiotoxicities underscore the importance of risk stratification, biomarker interpretation, and targeted escalation strategies, while revealing that generalized prophylaxis often yields modest benefits and should be mechanistically and clinically enriched [78,80,81,87,90,100].

Several priorities should guide future GRK2-directed translational research. First, patient stratification will likely need to move beyond single biomarkers and instead incorporate multi-parameter frameworks that combine troponin kinetics, global longitudinal strain, clinical risk features, metabolic characteristics, and mechanistically informative markers of immune activation [75,93]. Second, the development of compartment-selective GRK2 modulation remains an important goal, particularly strategies that limit pathologic mitochondrial GRK2 accumulation after injury without altering physiologic GPCR desensitization [11,12]. Third, increasing evidence from endothelial and fibroblast studies suggests that cell-type-directed delivery may offer a way to modulate immune recruitment and fibrosis while limiting systemic effects [10,16]. Finally, the potential of GRK2 as a biomarker axis should be tested prospectively. This includes PBMC GRK2 and GRK2-linked functional assays in both HF and cardio-oncology cohorts using guideline-aligned clinical and imaging endpoints [5,13,75]. Beyond its established role in GPCR desensitization, GRK2 has emerged as a multifunctional signaling molecule whose noncanonical activities may contribute directly to disease pathogenesis, presenting new opportunities for therapeutic targeting in context-specific pathologies.

Author Contributions: Conceptualization, C.R.D., P.Y.S.; Writing—original draft preparation, C.R.D., L.U., P.Y.S.; Writing—review and editing, L.U., P.Y.S.; Supervision, P.Y.S. All authors have read and agreed to the published version of the manuscript.

Funding: NHLBI R01HL163666 to P.Y.S.

Data Availability Statement: No data was generated for this review.

Acknowledgments: Figures were generated with Biorender Premium.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Bristow, M.R.; Ginsburg, R.; Minobe, W.; Cubicciotti, R.S.; Sageman, W.S.; Lurie, K.; Billingham, M.E.; Harrison, D.C.; Stinson, E.B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. *N. Engl. J. Med.* **1982**, *307*, 205–211. [\[CrossRef\]](#) [\[PubMed\]](#)
2. Bristow, M.R.; Ginsburg, R.; Umans, V.; Fowler, M.; Minobe, W.; Rasmussen, R.; Zera, P.; Menlove, R.; Shah, P.; Jamieson, S.; et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. *Circ. Res.* **1986**, *59*, 297–309. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Ungerer, M.; Bohm, M.; Elce, J.S.; Erdmann, E.; Lohse, M.J. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. *Circulation* **1993**, *87*, 454–463. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Bristow, M.R. Beta-adrenergic receptor blockade in chronic heart failure. *Circulation* **2000**, *101*, 558–569. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Iaccarino, G.; Barbato, E.; Cipolletta, E.; De Amicis, V.; Margulies, K.B.; Leosco, D.; Trimarco, B.; Koch, W.J. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. *Eur. Heart J.* **2005**, *26*, 1752–1758. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Belmonte, S.L.; Blaxall, B.C. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. *Circ. Res.* **2011**, *109*, 309–319. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Sato, P.Y.; Chuprun, J.K.; Schwartz, M.; Koch, W.J. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. *Physiol. Rev.* **2015**, *95*, 377–404. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Agüero, J.; Almenar, L.; Monto, F.; Oliver, E.; Sanchez-Lazaro, I.; Vicente, D.; Martinez-Dolz, L.; D’Ocon, P.; Rueda, J.; Salvador, A. Myocardial G protein receptor-coupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. *J. Card. Fail.* **2012**, *18*, 53–61. [\[CrossRef\]](#) [\[PubMed\]](#)
9. Penela, P.; Inserte, J.; Ramos, P.; Rodriguez-Sinovas, A.; Garcia-Dorado, D.; Mayor, F., Jr. Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion. *EBioMedicine* **2019**, *48*, 605–618. [\[CrossRef\]](#) [\[PubMed\]](#)
10. Woodall, M.C.; Woodall, B.P.; Gao, E.; Yuan, A.; Koch, W.J. Cardiac Fibroblast GRK2 Deletion Enhances Contractility and Remodeling Following Ischemia/Reperfusion Injury. *Circ. Res.* **2016**, *119*, 1116–1127. [\[CrossRef\]](#) [\[PubMed\]](#)
11. Chen, M.; Sato, P.Y.; Chuprun, J.K.; Peroutka, R.J.; Otis, N.J.; Ibbett, J.; Pan, S.; Sheu, S.S.; Gao, E.; Koch, W.J. Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting. *Circ. Res.* **2013**, *112*, 1121–1134. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Sato, P.Y.; Chuprun, J.K.; Grisanti, L.A.; Woodall, M.C.; Brown, B.R.; Roy, R.; Traynham, C.J.; Ibbett, J.; Lucchese, A.M.; Yuan, A.; et al. Restricting mitochondrial GRK2 post-ischemia confers cardioprotection by reducing myocyte death and maintaining glucose oxidation. *Sci. Signal.* **2018**, *11*, eaau0144. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Rengo, G.; Galasso, G.; Femminella, G.D.; Parisi, V.; Zincarelli, C.; Pagano, G.; De Lucia, C.; Cannavo, A.; Liccardo, D.; Marciano, C.; et al. Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. *Eur. J. Prev. Cardiol.* **2014**, *21*, 4–11. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Koch, W.J.; Rockman, H.A.; Samama, P.; Hamilton, R.A.; Bond, R.A.; Milano, C.A.; Lefkowitz, R.J. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. *Science* **1995**, *268*, 1350–1353. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Kuai, J.; Han, C.; Wei, W. Potential Regulatory Roles of GRK2 in Endothelial Cell Activity and Pathological Angiogenesis. *Front. Immunol.* **2021**, *12*, 698424. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Wu, L.D.; Shi, Y.; Kong, C.H.; Chen, A.Q.; Kang, Y.; Kan, J.Y.; Jiang, X.M.; Chu, P.; Wang, D.C.; Lv, Y.F.; et al. The GRK2/AP-1 Signaling Axis Mediates Vascular Endothelial Dysfunction and Atherosclerosis Induced by Oscillatory Low Shear Stress. *Adv. Sci.* **2025**, *12*, e01981. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Yang, X.Z.; Zhang, W.K.; Zhu, Z.Q.; Zhao, W.; Luo, L.L.; Wang, L.P.; Zhao, Y.J.; Chang, Y.; Wei, W. GRK2-mediated phosphorylation and de-succinylation of PKM2 reduce macrophage glycolysis in rheumatoid arthritis. *Acta Pharmacol. Sin.* **2025**, *46*, 2693–2706. [\[CrossRef\]](#) [\[PubMed\]](#)

18. Zhang, J.; Zhang, X.; Lu, M.; Chang, Y.; Wang, Q.; Tu, J.; Wu, H.; Wang, C.; Hong, Z.; Xiong, M.; et al. GRK2 Mediates Macrophage Polarization by Regulating EP4-cAMP-pCREB Signaling in Ulcerative Colitis and the Therapeutic Effect of Paroxetine on Mice with DSS-Induced Colitis. *Pharmaceuticals* **2023**, *16*, 664. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Glaser, K.M.; Tarrant, T.K.; Lammermann, T. Combinatorial depletions of G-protein coupled receptor kinases in immune cells identify pleiotropic and cell type-specific functions. *Front. Immunol.* **2022**, *13*, 1039803. [\[CrossRef\]](#) [\[PubMed\]](#)
20. Travers, J.G.; Schafer, A.E.; Blaxall, B.C. GRK2 in Lymphocytes: Expanding the Arsenal of Heart Failure Prognostics. *Circ. Res.* **2016**, *118*, 1049–1051. [\[CrossRef\]](#) [\[PubMed\]](#)
21. Bhutani, V.; Varzideh, F.; Wilson, S.; Kansakar, U.; Jankauskas, S.S.; Santulli, G. Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update. *J. Cardiovasc. Dev. Dis.* **2025**, *12*, 207. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Sheibani, M.; Azizi, Y.; Shayan, M.; Nezamoleslami, S.; Eslami, F.; Farjoo, M.H.; Dehpour, A.R. Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches. *Cardiovasc. Toxicol.* **2022**, *22*, 292–310. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Palaskas, N.L.; Ali, H.J.; Koutroumpakis, E.; Ganatra, S.; Deswal, A. Cardiovascular toxicity of immune therapies for cancer. *BMJ* **2024**, *385*, e075859. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Lympieropoulos, A.; Rengo, G.; Funakoshi, H.; Eckhart, A.D.; Koch, W.J. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. *Nat. Med.* **2007**, *13*, 315–323. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Lympieropoulos, A.; Rengo, G.; Gao, E.; Ebert, S.N.; Dorn, G.W., II; Koch, W.J. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. *J. Biol. Chem.* **2010**, *285*, 16378–16386. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Rengo, G.; Leosco, D.; Zincarelli, C.; Marchese, M.; Corbi, G.; Liccardo, D.; Filippelli, A.; Ferrara, N.; Lisanti, M.P.; Koch, W.J.; et al. Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. *Am. J. Physiol. Heart Circ. Physiol.* **2010**, *298*, H2032–H2038. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Tachibana, H.; Naga Prasad, S.V.; Lefkowitz, R.J.; Koch, W.J.; Rockman, H.A. Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. *Circulation* **2005**, *111*, 591–597. [\[CrossRef\]](#) [\[PubMed\]](#)
28. Eckhart, A.D.; Koch, W.J. Expression of a beta-adrenergic receptor kinase inhibitor reverses dysfunction in failing cardiomyocytes. *Mol. Ther.* **2002**, *5*, 74–79. [\[CrossRef\]](#) [\[PubMed\]](#)
29. Rockman, H.A.; Chien, K.R.; Choi, D.J.; Iaccarino, G.; Hunter, J.J.; Ross, J., Jr.; Lefkowitz, R.J.; Koch, W.J. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 7000–7005. [\[CrossRef\]](#) [\[PubMed\]](#)
30. Abd Alla, J.; Graemer, M.; Fu, X.; Quitterer, U. Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice. *J. Biol. Chem.* **2016**, *291*, 2583–2600. [\[CrossRef\]](#) [\[PubMed\]](#)
31. Roy, R.; Schumacher, S.M.; Murphy, H.C.; Grondolsky, J.; Rosales, T.O.; Chuprun, J.K.; Gao, E.; Zhao, H.; Berretta, R.M.; Hobby, A.R.H.; et al. Therapeutic Efficacy of a Novel Pharmacologic GRK2 Inhibitor in Multiple Animal Models of Heart Failure. *JACC Basic. Transl. Sci.* **2025**, *10*, 202–217. [\[CrossRef\]](#) [\[PubMed\]](#)
32. Schumacher, S.M.; Gao, E.; Zhu, W.; Chen, X.; Chuprun, J.K.; Feldman, A.M.; Tesmer, J.J.; Koch, W.J. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. *Sci. Transl. Med.* **2015**, *7*, 277ra231. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Raake, P.W.; Schlegel, P.; Ksienzyk, J.; Reinkober, J.; Barthelmes, J.; Schinkel, S.; Plegier, S.; Mier, W.; Haberkorn, U.; Koch, W.J.; et al. AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. *Eur. Heart J.* **2013**, *34*, 1437–1447. [\[CrossRef\]](#) [\[PubMed\]](#)
34. Raake, P.W.; Vinge, L.E.; Gao, E.; Boucher, M.; Rengo, G.; Chen, X.; De George, B.R., Jr.; Matkovich, S.; Houser, S.R.; Most, P.; et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. *Circ. Res.* **2008**, *103*, 413–422. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Fu, X.; Koller, S.; Abd Alla, J.; Quitterer, U. Inhibition of G-protein-coupled receptor kinase 2 (GRK2) triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway. *J. Biol. Chem.* **2013**, *288*, 7738–7755. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Thal, D.M.; Homan, K.T.; Chen, J.; Wu, E.K.; Hinkle, P.M.; Huang, Z.M.; Chuprun, J.K.; Song, J.; Gao, E.; Cheung, J.Y.; et al. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. *ACS Chem. Biol.* **2012**, *7*, 1830–1839. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Homan, K.T.; Wu, E.; Wilson, M.W.; Singh, P.; Larsen, S.D.; Tesmer, J.J. Structural and functional analysis of g protein-coupled receptor kinase inhibition by paroxetine and a rationally designed analog. *Mol. Pharmacol.* **2014**, *85*, 237–248. [\[CrossRef\]](#)
38. Sato, P.Y.; Chuprun, J.K.; Ibeti, J.; Cannavo, A.; Drosatos, K.; Elrod, J.W.; Koch, W.J. GRK2 compromises cardiomyocyte mitochondrial function by diminishing fatty acid-mediated oxygen consumption and increasing superoxide levels. *J. Mol. Cell Cardiol.* **2015**, *89*, 360–364. [\[CrossRef\]](#) [\[PubMed\]](#)

39. Casey, L.M.; Pistner, A.R.; Belmonte, S.L.; Migdalovich, D.; Stolpnik, O.; Nwakanma, F.E.; Vorobiof, G.; Dunaevsky, O.; Matavel, A.; Lopes, C.M.; et al. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. *Circ. Res.* **2010**, *107*, 532–539. [[CrossRef](#)] [[PubMed](#)]
40. Lopaschuk, G.D.; Karwi, Q.G.; Tian, R.; Wende, A.R.; Abel, E.D. Cardiac Energy Metabolism in Heart Failure. *Circ. Res.* **2021**, *128*, 1487–1513. [[CrossRef](#)] [[PubMed](#)]
41. Ciccarelli, M.; Chuprun, J.K.; Rengo, G.; Gao, E.; Wei, Z.; Peroutka, R.J.; Gold, J.I.; Gumpert, A.; Chen, M.; Otis, N.J.; et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. *Circulation* **2011**, *123*, 1953–1962. [[CrossRef](#)] [[PubMed](#)]
42. Snyder, J.; Jiang, C.S.; Choi, R.H.; Morgan, T.; Roman, J.; Underwood, L.; Lucchese, A.M.; Montgomery, S.; Grisanti, L.A.; Doliba, N.; et al. Cardioprotective effect of genetic ablation of the G-protein-coupled receptor kinase GRK2 in adult pancreatic beta-cells during high-fat diet. *J. Biol. Chem.* **2025**, *301*, 108388. [[CrossRef](#)] [[PubMed](#)]
43. Ciccarelli, M.; Sorriento, D.; Fiordelisi, A.; Gambardella, J.; Franco, A.; Del Giudice, C.; Sala, M.; Monti, M.G.; Bertamino, A.; Campiglia, P.; et al. Pharmacological inhibition of GRK2 improves cardiac metabolism and function in experimental heart failure. *ESC Heart Fail.* **2020**, *7*, 1571–1584. [[CrossRef](#)] [[PubMed](#)]
44. Motso, A.; Pelcman, B.; Kalinovich, A.; Kahlous, N.A.; Bokhari, M.H.; Dehvari, N.; Halleskog, C.; Waara, E.; de Jong, J.; Cheesman, E.; et al. GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. *Cell* **2025**, *188*, 5142–5156 e5123. [[CrossRef](#)] [[PubMed](#)]
45. Lucas, E.; Jurado-Pueyo, M.; Fortuno, M.A.; Fernandez-Veledo, S.; Vila-Bedmar, R.; Jimenez-Borreguero, L.J.; Lazcano, J.J.; Gao, E.; Gomez-Ambrosi, J.; Fruhbeck, G.; et al. Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns. *Biochim. Biophys. Acta* **2014**, *1842*, 2448–2456. [[CrossRef](#)] [[PubMed](#)]
46. Arcones, A.C.; Vila-Bedmar, R.; Mirasierra, M.; Cruces-Sande, M.; Vallejo, M.; Jones, B.; Tomas, A.; Mayor, F., Jr.; Murga, C. GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo. *BMC Biol.* **2021**, *19*, 40. [[CrossRef](#)] [[PubMed](#)]
47. Cannavo, A.; Liccardo, D.; Lymperopoulos, A.; Santangelo, M.; Femminella, G.D.; Leosco, D.; Cittadini, A.; Ferrara, N.; Paolucci, N.; Koch, W.J.; et al. GRK2 Regulates alpha(2)-Adrenergic Receptor-Dependent Catecholamine Release in Human Adrenal Chromaffin Cells. *J. Am. Coll. Cardiol.* **2017**, *69*, 1515–1517. [[CrossRef](#)] [[PubMed](#)]
48. Luo, J.; Benovic, J.L. G protein-coupled receptor kinase interaction with Hsp90 mediates kinase maturation. *J. Biol. Chem.* **2003**, *278*, 50908–50914. [[CrossRef](#)] [[PubMed](#)]
49. Fan, Q.; Chen, M.; Zuo, L.; Shang, X.; Huang, M.Z.; Ciccarelli, M.; Raake, P.; Brinks, H.; Chuprun, K.J.; Dorn, G.W., II; et al. Myocardial Ablation of G Protein-Coupled Receptor Kinase 2 (GRK2) Decreases Ischemia/Reperfusion Injury through an Anti-Intrinsic Apoptotic Pathway. *PLoS ONE* **2013**, *8*, e66234. [[CrossRef](#)] [[PubMed](#)]
50. Brinks, H.; Boucher, M.; Gao, E.; Chuprun, J.K.; Pesant, S.; Raake, P.W.; Huang, Z.M.; Wang, X.; Qiu, G.; Gumpert, A.; et al. Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. *Circ. Res.* **2010**, *107*, 1140–1149. [[CrossRef](#)] [[PubMed](#)]
51. Nandagopal, K.; Dawson, T.M.; Dawson, V.L. Critical role for nitric oxide signaling in cardiac and neuronal ischemic preconditioning and tolerance. *J. Pharmacol. Exp. Ther.* **2001**, *297*, 474–478. [[CrossRef](#)]
52. Schulz, R.; Kelm, M.; Heusch, G. Nitric oxide in myocardial ischemia/reperfusion injury. *Cardiovasc. Res.* **2004**, *61*, 402–413. [[CrossRef](#)] [[PubMed](#)]
53. Gould, N.; Doulias, P.T.; Tenopoulou, M.; Raju, K.; Ischiropoulos, H. Regulation of protein function and signaling by reversible cysteine S-nitrosylation. *J. Biol. Chem.* **2013**, *288*, 26473–26479. [[CrossRef](#)] [[PubMed](#)]
54. Huang, Z.M.; Gao, E.; Fonseca, F.V.; Hayashi, H.; Shang, X.; Hoffman, N.E.; Chuprun, J.K.; Tian, X.; Tilley, D.G.; Madesh, M.; et al. Convergence of G protein-coupled receptor and S-nitrosylation signaling determines the outcome to cardiac ischemic injury. *Sci. Signal.* **2013**, *6*, ra95. [[CrossRef](#)] [[PubMed](#)]
55. Whalen, E.J.; Foster, M.W.; Matsumoto, A.; Ozawa, K.; Violin, J.D.; Que, L.G.; Nelson, C.D.; Benhar, M.; Keys, J.R.; Rockman, H.A.; et al. Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. *Cell* **2007**, *129*, 511–522. [[CrossRef](#)] [[PubMed](#)]
56. Lieu, M.; Traynham, C.J.; de Lucia, C.; Pfleger, J.; Piedepalumbo, M.; Roy, R.; Petovic, J.; Landesberg, G.; Forrester, S.J.; Hoffman, M.; et al. Loss of dynamic regulation of G protein-coupled receptor kinase 2 by nitric oxide leads to cardiovascular dysfunction with aging. *Am. J. Physiol. Heart Circ. Physiol.* **2020**, *318*, H1162–H1175. [[CrossRef](#)] [[PubMed](#)]
57. Krasel, C.; Dammeier, S.; Winstel, R.; Brockmann, J.; Mischak, H.; Lohse, M.J. Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by calmodulin. *J. Biol. Chem.* **2001**, *276*, 1911–1915. [[CrossRef](#)] [[PubMed](#)]
58. Ciccarelli, M.; Sorriento, D.; Franco, A.; Fusco, A.; Del Giudice, C.; Annunziata, R.; Cipolletta, E.; Monti, M.G.; Dorn, G.W., II; Trimarco, B.; et al. Endothelial G protein-coupled receptor kinase 2 regulates vascular homeostasis through the control of free radical oxygen species. *Arterioscler. Thromb. Vasc. Biol.* **2013**, *33*, 2415–2424. [[CrossRef](#)] [[PubMed](#)]

59. Liu, S.; Premont, R.T.; Kontos, C.D.; Zhu, S.; Rockey, D.C. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. *Nat. Med.* **2005**, *11*, 952–958. [[CrossRef](#)] [[PubMed](#)]
60. Dick, S.A.; Macklin, J.A.; Nejat, S.; Momen, A.; Clemente-Casares, X.; Althagafi, M.G.; Chen, J.; Kantores, C.; Hosseinzadeh, S.; Aronoff, L.; et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. *Nat. Immunol.* **2019**, *20*, 29–39. [[CrossRef](#)] [[PubMed](#)]
61. Li, W.; Hsiao, H.M.; Higashikubo, R.; Saunders, B.T.; Bharat, A.; Goldstein, D.R.; Krupnick, A.S.; Gelman, A.E.; Lavine, K.J.; Kreisel, D. Heart-resident CCR2(+) macrophages promote neutrophil extravasation through TLR9/MyD88/CXCL5 signaling. *JCI Insight* **2016**, *1*, e87315. [[CrossRef](#)] [[PubMed](#)]
62. Nahrendorf, M.; Swirski, F.K.; Aikawa, E.; Stangenberg, L.; Wurdinger, T.; Figueiredo, J.L.; Libby, P.; Weissleder, R.; Pittet, M.J. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. *J. Exp. Med.* **2007**, *204*, 3037–3047. [[CrossRef](#)] [[PubMed](#)]
63. Stevenson, N.L.; Martin-Martin, B.; Freeman, J.; Kriston-Vizi, J.; Ketteler, R.; Cutler, D.F. G protein-coupled receptor kinase 2 moderates recruitment of THP-1 cells to the endothelium by limiting histamine-invoked Weibel-Palade body exocytosis. *J. Thromb. Haemost.* **2014**, *12*, 261–272. [[CrossRef](#)] [[PubMed](#)]
64. Cassarino, M.C.; Colado, A.; Martinez, V.S.; Martinez, C.; Bonato, A.; Bertini, M.; Pavlovksy, M.; Custidiano, R.; Bezares, F.R.; Morande, P.E.; et al. G-protein coupled receptor kinase-2 regulates the migration of chronic lymphocytic leukaemia cells to sphingosine-1 phosphate in vitro and their trafficking in vivo. *Sci. Rep.* **2025**, *15*, 6530. [[CrossRef](#)] [[PubMed](#)]
65. Cheng, J.; Lucas, P.C.; McAllister-Lucas, L.M. Canonical and Non-Canonical Roles of GRK2 in Lymphocytes. *Cells* **2021**, *10*, 307. [[CrossRef](#)] [[PubMed](#)]
66. Lavine, K.J.; Epelman, S.; Uchida, K.; Weber, K.J.; Nichols, C.G.; Schilling, J.D.; Ornitz, D.M.; Randolph, G.J.; Mann, D.L. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 16029–16034. [[CrossRef](#)] [[PubMed](#)]
67. Kadyrov, F.F.; Koenig, A.L.; Amrute, J.M.; Dun, H.; Li, W.; Weinheimer, C.J.; Nigro, J.M.; Kovacs, A.; Bredemeyer, A.L.; Yang, S.; et al. Hypoxia sensing in resident cardiac macrophages regulates monocyte fate specification following ischemic heart injury. *Nat. Cardiovasc. Res.* **2024**, *3*, 1337–1355. [[CrossRef](#)] [[PubMed](#)]
68. Liu, Y.; Xu, R.; Gu, H.; Zhang, E.; Qu, J.; Cao, W.; Huang, X.; Yan, H.; He, J.; Cai, Z. Metabolic reprogramming in macrophage responses. *Biomark. Res.* **2021**, *9*, 1. [[CrossRef](#)] [[PubMed](#)]
69. Van den Bossche, J.; O'Neill, L.A.; Menon, D. Macrophage Immunometabolism: Where Are We (Going)? *Trends Immunol.* **2017**, *38*, 395–406. [[CrossRef](#)] [[PubMed](#)]
70. Yan, X.; Anzai, A.; Katsumata, Y.; Matsushashi, T.; Ito, K.; Endo, J.; Yamamoto, T.; Takeshima, A.; Shinmura, K.; Shen, W.; et al. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. *J. Mol. Cell Cardiol.* **2013**, *62*, 24–35. [[CrossRef](#)] [[PubMed](#)]
71. de Winter, N.; Ji, J.; Sintou, A.; Forte, E.; Lee, M.; Nosedà, M.; Li, A.; Koenig, A.L.; Lavine, K.J.; Hayat, S.; et al. Persistent transcriptional changes in cardiac adaptive immune cells following myocardial infarction: New evidence from the re-analysis of publicly available single cell and nuclei RNA-sequencing data sets. *J. Mol. Cell Cardiol.* **2024**, *192*, 48–64. [[CrossRef](#)] [[PubMed](#)]
72. Dinkel, B.A.; Kremer, K.N.; Rollins, M.R.; Medlyn, M.J.; Hedin, K.E. GRK2 mediates TCR-induced transactivation of CXCR4 and TCR-CXCR4 complex formation that drives PI3Kgamma/PREX1 signaling and T cell cytokine secretion. *J. Biol. Chem.* **2018**, *293*, 14022–14039. [[CrossRef](#)] [[PubMed](#)]
73. Arnon, T.I.; Xu, Y.; Lo, C.; Pham, T.; An, J.; Coughlin, S.; Dorn, G.W.; Cyster, J.G. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. *Science* **2011**, *333*, 1898–1903. [[CrossRef](#)] [[PubMed](#)]
74. Herrmann, J.; Lenihan, D.; Armenian, S.; Barac, A.; Blaes, A.; Cardinale, D.; Carver, J.; Dent, S.; Ky, B.; Lyon, A.R.; et al. Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement. *Eur. Heart J.* **2022**, *43*, 280–299. [[CrossRef](#)] [[PubMed](#)]
75. Lyon, A.R.; Lopez-Fernandez, T.; Couch, L.S.; Asteggiano, R.; Aznar, M.C.; Bergler-Klein, J.; Boriani, G.; Cardinale, D.; Cordoba, R.; Cosyns, B.; et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur. Heart J.* **2022**, *43*, 4229–4361. [[CrossRef](#)] [[PubMed](#)]
76. Babuin, L.; Jaffe, A.S. Troponin: The biomarker of choice for the detection of cardiac injury. *CMAJ* **2005**, *173*, 1191–1202. [[CrossRef](#)] [[PubMed](#)]
77. Cardinale, D.; Colombo, A.; Sandri, M.T.; Lamantia, G.; Colombo, N.; Civelli, M.; Martinelli, G.; Veglia, F.; Fiorentini, C.; Cipolla, C.M. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. *Circulation* **2006**, *114*, 2474–2481. [[CrossRef](#)] [[PubMed](#)]
78. Cardinale, D.; Ciceri, F.; Latini, R.; Franzosi, M.G.; Sandri, M.T.; Civelli, M.; Cucchi, G.; Menatti, E.; Mangiavacchi, M.; Cavina, R.; et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. *Eur. J. Cancer* **2018**, *94*, 126–137. [[CrossRef](#)] [[PubMed](#)]

79. Henriksen, P.A.; Hall, P.; Oikonomidou, O.; MacPherson, I.R.; Maclean, M.; Lewis, S.; McVicars, H.; Broom, A.; Scott, F.; McKay, P.; et al. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. *Circ. Heart Fail.* **2022**, *15*, e009445. [[CrossRef](#)] [[PubMed](#)]
80. Gulati, G.; Heck, S.L.; Ree, A.H.; Hoffmann, P.; Schulz-Menger, J.; Fagerland, M.W.; Gravdehaug, B.; von Knobelsdorff-Brenkenhoff, F.; Bratland, A.; Storås, T.H.; et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Eur. Heart J.* **2016**, *37*, 1671–1680. [[CrossRef](#)] [[PubMed](#)]
81. Avila, M.S.; Ayub-Ferreira, S.M.; de Barros Wanderley, M.R., Jr.; das Dores Cruz, F.; Goncalves Brandao, S.M.; Rigaud, V.O.C.; Higuchi-Dos-Santos, M.H.; Hajjar, L.A.; Kalil Filho, R.; Hoff, P.M.; et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. *J. Am. Coll. Cardiol.* **2018**, *71*, 2281–2290. [[CrossRef](#)] [[PubMed](#)]
82. Swain, S.M.; Whaley, F.S.; Gerber, M.C.; Weisberg, S.; York, M.; Spicer, D.; Jones, S.E.; Wadler, S.; Desai, A.; Vogel, C.; et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. *J. Clin. Oncol.* **1997**, *15*, 1318–1332. [[CrossRef](#)] [[PubMed](#)]
83. Marty, M.; Espie, M.; Llombart, A.; Monnier, A.; Rapoport, B.L.; Stahalova, V. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. *Ann. Oncol.* **2006**, *17*, 614–622. [[CrossRef](#)] [[PubMed](#)]
84. de Baat, E.C.; Mulder, R.L.; Armenian, S.; Feijen, E.A.; Grotenhuis, H.; Hudson, M.M.; Mavinkurve-Groothuis, A.M.; Kremer, L.C.; van Dalen, E.C. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. *Cochrane Database Syst. Rev.* **2022**, *9*, CD014638. [[CrossRef](#)] [[PubMed](#)]
85. Macedo, A.V.S.; Hajjar, L.A.; Lyon, A.R.; Nascimento, B.R.; Putzu, A.; Rossi, L.; Costa, R.B.; Landoni, G.; Nogueira-Rodrigues, A.; Ribeiro, A.L.P. Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer. *JACC Cardio Oncol.* **2019**, *1*, 68–79. [[CrossRef](#)] [[PubMed](#)]
86. Junjing, Z.; Yan, Z.; Baolu, Z. Scavenging effects of dexrazoxane on free radicals. *J. Clin. Biochem. Nutr.* **2010**, *47*, 238–245. [[CrossRef](#)] [[PubMed](#)]
87. Nielsen, D.L.; Juhl, C.B.; Nielsen, O.H.; Chen, I.M.; Herrmann, J. Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. *JAMA Oncol.* **2024**, *10*, 1390–1399. [[CrossRef](#)] [[PubMed](#)]
88. Bencivenga, L.; Palaia, M.E.; Sepe, I.; Gambino, G.; Komici, K.; Cannavo, A.; Femminella, G.D.; Rengo, G. Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New Biomarker? *Cells* **2021**, *10*, 457. [[CrossRef](#)] [[PubMed](#)]
89. Johnson, D.B.; Balko, J.M.; Compton, M.L.; Chalkias, S.; Gorham, J.; Xu, Y.; Hicks, M.; Puzanov, I.; Alexander, M.R.; Bloomer, T.L.; et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *N. Engl. J. Med.* **2016**, *375*, 1749–1755. [[CrossRef](#)] [[PubMed](#)]
90. Mahmood, S.S.; Fradley, M.G.; Cohen, J.V.; Nohria, A.; Reynolds, K.L.; Heinzerling, L.M.; Sullivan, R.J.; Damrongwatanasuk, R.; Chen, C.L.; Gupta, D.; et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. *J. Am. Coll. Cardiol.* **2018**, *71*, 1755–1764. [[CrossRef](#)] [[PubMed](#)]
91. Fenioux, C.; Abbar, B.; Boussouar, S.; Bretagne, M.; Power, J.R.; Moslehi, J.J.; Gougis, P.; Amelin, D.; Dechartres, A.; Lehmann, L.H.; et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. *Nat. Med.* **2023**, *29*, 3100–3110. [[CrossRef](#)] [[PubMed](#)]
92. Palaskas, N.L.; Segura, A.; Lelenwa, L.; Siddiqui, B.A.; Subudhi, S.K.; Lopez-Mattei, J.; Durand, J.B.; Deswal, A.; Zhao, B.; Maximilian Buja, L.; et al. Immune checkpoint inhibitor myocarditis: Elucidating the spectrum of disease through endomyocardial biopsy. *Eur. J. Heart Fail.* **2021**, *23*, 1725–1735. [[CrossRef](#)] [[PubMed](#)]
93. Delombaerde, D.; Vervloet, D.; Franssen, C.; Croes, L.; Gremontprez, F.; Prenen, H.; Peeters, M.; Vulsteke, C. Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. *ESMO Open* **2021**, *6*, 100216. [[CrossRef](#)] [[PubMed](#)]
94. Munir, A.Z.; Gutierrez, A.; Qin, J.; Lichtman, A.H.; Moslehi, J.J. Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart. *Nat. Rev. Cancer.* **2024**, *24*, 540–553. [[CrossRef](#)] [[PubMed](#)]
95. Ma, P.; Liu, J.; Qin, J.; Lai, L.; Heo, G.S.; Luehmann, H.; Sultan, D.; Bredemeyer, A.; Bajapa, G.; Feng, G.; et al. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis. *Circulation* **2024**, *149*, 48–66. [[CrossRef](#)] [[PubMed](#)]
96. Huang, Y.V.; Sun, Y.; Chou, H.; Wagner, N.; Vitale, M.R.; Bayer, A.L.; Xu, B.; Lee, D.; Lin, Z.; Branche, C.; et al. Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis. *Circ. Res.* **2025**, *136*, 473–490. [[CrossRef](#)] [[PubMed](#)]
97. Gardner, J.; Eiger, D.S.; Hicks, C.; Choi, I.; Pham, U.; Chundi, A.; Namjoshi, O.; Rajagopal, S. GPCR kinases differentially modulate biased signaling downstream of CXCR3 depending on their subcellular localization. *Sci. Signal.* **2024**, *17*, eadd9139. [[CrossRef](#)] [[PubMed](#)]
98. Hachem, A.M.; Desai, A.; Beinart, N.; Ostos-Mendoza, K.C.; Rodriguez, A.S.L.; de Leon Derby, R.D.; Ebrahimi, S.; Palaskas, N.L. Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis. *Curr. Cardiol. Rep.* **2025**, *27*, 78. [[CrossRef](#)] [[PubMed](#)]

99. Salem, J.E.; Allenbach, Y.; Vozy, A.; Brechot, N.; Johnson, D.B.; Moslehi, J.J.; Kerneis, M. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. *N. Engl. J. Med.* **2019**, *380*, 2377–2379. [[CrossRef](#)] [[PubMed](#)]
100. Zhang, L.; Zlotoff, D.A.; Awadalla, M.; Mahmood, S.S.; Nohria, A.; Hassan, M.Z.O.; Thuny, F.; Zubiri, L.; Chen, C.L.; Sullivan, R.J.; et al. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. *Circulation* **2020**, *141*, 2031–2034. [[CrossRef](#)] [[PubMed](#)]
101. Waldschmidt, H.V.; Homan, K.T.; Cato, M.C.; Cruz-Rodriguez, O.; Cannavo, A.; Wilson, M.W.; Song, J.; Cheung, J.Y.; Koch, W.J.; Tesmer, J.J.; et al. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine. *J. Med. Chem.* **2017**, *60*, 3052–3069. [[CrossRef](#)] [[PubMed](#)]
102. Lai, S.; Fu, X.; Yang, S.; Zhang, S.; Lin, Q.; Zhang, M.; Chen, H. G protein-coupled receptor kinase-2: A potential biomarker for early diabetic cardiomyopathy. *J. Diabetes.* **2020**, *12*, 247–258. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.